Sera Prognostics Announces Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 29



SALT LAKE CITY, March 18, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and newborn health by providing innovative pregnancy biomarker information to physicians and patients, announced today today that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022, after market close. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics to be discussed. 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly released prior to the call.

Conference call details:

National calls in the United States: (877) 870-4263
International calls: (412) 317-0790

Webcast registration link:

Live audio of the webcast will be available online from the Investors page of the Company’s website at The webcast will be archived on the Investors page and will be available for one year.

About Sera Prognostics, Inc.

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide physicians with crucial and early information about pregnancy, enabling them to improve the health of their patients, which translates into lower costs of providing healthcare. Sera has a strong portfolio of innovative diagnostic tests focused on early prediction of the risk of preterm birth and other pregnancy complications. Sera’s PreTRM® precision medicine test alerts a physician to the individualized risk of spontaneous preterm birth during a pregnancy, enabling earlier proactive interventions in women at higher risk. Sera Prognostics is located at Salt Lake City, UT.

About premature birth

Premature birth is defined as any birth before 37 weeks of gestation and is the leading cause of illness and death in newborns. The 2021 March of Dimes report card shows that more than one in ten children are born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory disease, intellectual disability, seizures, and loss of vision and hearing, and can generate significant costs throughout the life of affected children. Annual health care costs to manage short-term and long-term complications of prematurity United States were estimated at approximately $25 billion for 2016.

About PreMRT® Test

The PreTRM® test is the only widely validated and commercially available blood biomarker test that provides an early, accurate and individualized prediction of the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of premature birth. The PreTRM® test allows physicians to identify, during the 19th or 20th week of pregnancy, which women are at increased risk of preterm birth, allowing for more informed and personalized clinical decisions based on individual risk. of every woman. The PreTRM® test is ordered by a healthcare professional.

Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. United States and/or other countries.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date, time and content of the quarterly earnings release and conference call. of the society ; and corporate strategic guidelines under the heading “About Sera Prognostics, Inc.” These “forward-looking statements” are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those stated or implied. understood by the forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation and the potential need to raise further capital; revenue from the PreTRM test representing almost all of the Company’s revenue to date; the need for broad scientific and commercial acceptance of the PreTRM test; a concentrated number of large customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as well as the businesses or operations of third parties with whom we do business; estimates of total addressable market opportunities and market growth forecasts; potential third-party payment coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM test, including new CPT codes and payment rates for these codes; changes in FDA regulations on laboratory-developed tests; intellectual property rights protecting our testing and market position; and other factors discussed under “Risk Factors” contained in our final prospectus on Form S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to these risk factors filed from time to time in our Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K or Current Reports on Form 8-K. All information contained in this press release is as of the date of publication, and the Company undertakes no obligation to update this information, except as required by law.

Quote Show original content to download multimedia: 29-301505515.html

SOURCE Sera Prognostics, Inc.

Source link


Comments are closed.